Connect your AI

Arcus Biosciences RCUS Long-term debt, gross

Long-term debt, gross at other companies

Jazz PharmaceuticalsJAZZ

——

Arcutis Biotherapeutics, Inc.ARQT

——

Other financials

Income statement

Revenue$17.0M-39.3%

Operating income-$134.0M-9.8%

Net income-$128.0M-14.3%

EPS (diluted)-$1.02+10.5%

Balance sheet

Cash & equivalents$201.0M+4.7%

Total debt$113.0M+88.3%

Total equity$524.0M-1.3%

Total assets$997.0M-13.8%

Cash flow

Operating cash flow-$138.0M-4.5%

CapEx--100%

Free cash flow-$138.0M-3.8%

Valuation

Market cap$3.54B+226%

Enterprise value$3.46B+275%

P/S15×+7.3×

Profitability

Operating margin-168.6%-52.7pp

Net margin-156.4%-47.5pp

FCF margin-207.2%—

Returns & leverage

Return on equity-70%+8.4pp

Debt / equity0.2×+0.1×

Current ratio4×-1.3×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentCarryingAmount.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's long-term debt, gross.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Arcus Biosciences's long-term debt, gross?: Arcus Biosciences (RCUS) reported long-term debt, gross of $100M in Q1 2026.
How has Arcus Biosciences's long-term debt, gross changed year-over-year?: Arcus Biosciences's long-term debt, gross increased by 100.0% year-over-year, from $50M to $100M.